NCT00398502已完成1 期
A Randomized, Open-label, 3-period Crossover Study to Determine the Relative Bioavailability of Two Oral Formulations of MOA-728 and to Compare the Pharmacodynamics of the Two Oral Formulations of MOA-728 and the Subcutaneous Formulation in Subjects on Stable Methadone Maintenance
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 试验地点
- 1
- 主要终点
- Pharmacokinetics and Pharmacodynamics
研究概览
简要总结
Primary: To determine the relative bioavailability of MOA-728, an investigational drug, administered orally in both the capsule and tablet formulations to methadone maintenance subjects.Secondary: To assess the pharmacodynamic effect of MOA-728 administered both orally and subcutaneously to methadone maintenance subjects using the oral-cecal transit time.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men or nonlactating and nonpregnant women, aged 18 to 65 years, inclusive. Women of nonchildbearing potential must be surgically sterile (hysterectomy, oophorectomy, and/or tubal ligation) or postmenopausal for ³1 year. Women of childbearing potential must be using an acceptable nonhormonal method of contraception (intrauterine device [IUD], diaphragm, or condom with spermicidal jelly or foam, or abstinence) for a period of at least 1 month before and after dose administration. All women must have negative pregnancy test results within 48 hours before the start of the first test article administration.
- •Body mass index in the range of 18 to 35 kg/m² and body weight ≥50 kg.
- •Healthy as determined by the investigator on the basis of medical history, physical examination, clinical laboratory test results, vital signs, and 12-lead electrocardiogram (ECG).
- •Subjects with positive results for HBsAg, and/or HCV antibodies may be enrolled if their bilirubin and serum albumin values are within normal limits and their liver function tests are within 1.2 times the upper limit of the normal range.
- •A history of methadone treatment for at least 1 month before day -1 and have a positive drug test for methadone.
- •No concomitant medication with the exception of stable doses of anxiolytic agents, antidepressants, Seroquel, occasional sleep medications, and drugs or supplements required to enhance or maintain regulation of bowel movements (must be stopped for the 72 hours before the first dose of test article administration in each period).
- •Must have a high probability for compliance with and completion of the study.
排除标准
- 未提供
结局指标
主要结局
Pharmacokinetics and Pharmacodynamics
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Relative Bioavailability Trial of Dapivirine Ring-004 and Ring-008HIV InfectionsNCT05416021International Partnership for Microbicides, Inc.124
已完成
1 期
A Study to Assess the Relative Bioavailability of TMC207 Following Single-Dose Administrations of Two Pediatric Formulations in Healthy Adult ParticipantsHealthyBiological AvailabilityNCT01803373Janssen Infectious Diseases BVBA36
已完成
1 期
A Relative Bioavailability Food Effect Study of LY03005Major Depressive DisorderNCT03822065Luye Pharma Group Ltd.34
已完成
1 期
A Pilot Open-Label Crossover Bioavailability Study of Celecoxib in Healthy VolunteersHealthy VolunteersNCT00813241Pfizer's Upjohn has merged with Mylan to form Viatris Inc.16
已完成
1 期
A Study Evaluating the Relative Bioavailability of Lofexidine Granules for Reconstitution Compared to LUCEMYRA (Lofexidine) Tablets and the Effect of Food on the Bioavailability of the Lofexidine Granules for ReconstitutionNormal Healthy VolunteersNCT04188730USWM, LLC (dba US WorldMeds)16